Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 1:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 361 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Pen device Clear all
Completed Phase 1 Interventional Results available

Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma

NCT00398138
View directory record Official record
Conditions
Leukemia, Lung Cancer, Malignant Mesothelioma, Myelodysplastic Syndromes, Primary Peritoneal Cavity Cancer
Interventions
WT-1 analog peptide vaccine, incomplete Freund's adjuvant, sargramostim, polymerase chain reaction, flow cytometry, immunoenzyme technique
Biological · Genetic · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 1, 2016 · Synced Sep 7, 2026, 1:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Reliability and Equivalence of Alternate Forms of the Digital Clock Drawing Test

NCT04496752
View directory record Official record
Conditions
Cognitive Function
Interventions
DCTclock
Device
Lead sponsor
Linus Health, Inc.
Industry
Eligibility
55 Years to 95 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Maitland, Florida • Eatontown, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Sep 7, 2026, 1:29 PM EDT
Completed Phase 2 Interventional Results available

G-Pen™ for Hypoglycemia Rescue in T1D Patients

NCT02423980
View directory record Official record
Conditions
Hypoglycemia
Interventions
Glucagon
Drug
Lead sponsor
Xeris Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Walnut Creek, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Sep 7, 2026, 1:29 PM EDT
Not listed Phase 2 Interventional

Wake up Symptomatic Stroke - Benefit of Intravenous Clot Busters or Endovascular Intervention

NCT01455935
View directory record Official record
Conditions
Stroke
Interventions
Anti-platelets and statin, alteplase, intra arterial intervention
Drug · Procedure
Lead sponsor
Jacobs Neurological Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 29, 2012 · Synced Sep 7, 2026, 1:29 PM EDT
Completed Phase 3 Interventional Results available

Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)

NCT02023879
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Alirocumab, Placebo (for Alirocumab), Non-statin LMT, Diet Alone
Drug · Other
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
8
States / cities
Beverly Hills, California • Atlantis, Florida • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Sep 7, 2026, 1:29 PM EDT
Completed Phase 4 Interventional Results available

Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure

NCT01117350
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin glargine, Liraglutide, Metformin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
35 Years to 75 Years
Enrollment
978 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
45
States / cities
Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2014 · Synced Sep 7, 2026, 1:29 PM EDT
Recruiting Not applicable Interventional

Trial of Partial Enteral Nutrition With Dairy Free Diet in Eosinophilic Esophagitis

NCT07234825
View directory record Official record
Conditions
Eosinophilic Esophagitis (EoE)
Interventions
Partial enteral nutrition (PEN) with dairy elimination, Dairy elimination alone
Other
Lead sponsor
Kate Farms Inc
Industry
Eligibility
1 Year to 21 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 7, 2026, 1:29 PM EDT
Recruiting Phase 1Phase 2 Interventional

Feasibility of Semaglutide in Advanced Lung Disease

NCT05746039
View directory record Official record
Conditions
Obesity, Interstitial Lung Disease, Chronic Obstructive Pulmonary Disease, Sarcoidosis, Pulmonary, Pulmonary Hypertension
Interventions
Semaglutide Pen Injector
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 7, 2026, 1:29 PM EDT
Completed Phase 4 Interventional Results available

A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)

NCT05564039
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Tirzepatide, Dulaglutide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
11
States / cities
Cooper City, Florida • West Palm Beach, Florida • Skokie, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2025 · Synced Sep 7, 2026, 1:29 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Preference Study of a Insulin Pen PDS290 vs. a Novo Nordisk Marketed Insulin Pen in Diabetics

NCT00773279
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Delivery Systems
Interventions
FlexTouch®, FlexPen®
Device
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
65
States / cities
Burlingame, California • Concord, California • Encino, California + 59 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2017 · Synced Sep 7, 2026, 1:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioavailability of Risankizumab Following Subcutaneous Administration With Prefilled Pen Relative to a Prefilled Syringe in Healthy Adult Participants

NCT06946524
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Risankizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 60 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
Cypress, California • Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 25, 2025 · Synced Sep 7, 2026, 1:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of PF-06410293 Following Subcutaneous Administration Using A Prefilled Syringe Or A Prefilled Pen In Healthy Adult Subjects

NCT02572245
View directory record Official record
Conditions
Healthy Subjects
Interventions
PF-06410293 PFS, PF-06410293 PFP
Device
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
164 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2016 · Synced Sep 7, 2026, 1:29 PM EDT
Completed Phase 3 Interventional Results available

Study of the Experience of Patients With Osteoporosis Using the Forteo B Pen to Self Administer Once Daily Teriparatide Therapy

NCT00577863
View directory record Official record
Conditions
Osteoporosis
Interventions
teriparatide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
18
States / cities
Huntsville, Alabama • Montgomery, Alabama • Peoria, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2009 · Synced Sep 7, 2026, 1:29 PM EDT
Recruiting Not applicable Interventional

Discogen for Low Back Pain

NCT06611397
View directory record Official record
Conditions
Disc Herniation
Interventions
Discogen Low pulsed ultrasound treatment, Discogen Sham Treatment
Device
Lead sponsor
Columbia University
Other
Eligibility
21 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 7, 2026, 1:29 PM EDT
Active, not recruiting Not applicable Interventional

Electronic Neurocognitive Tools in Screening for Mental Capability in Patients Undergoing Liver Surgery

NCT03678441
View directory record Official record
Conditions
Liver and Intrahepatic Bile Duct Disorder
Interventions
BrainCheck Cognitive Assessment, Cognitive Assessment
Behavioral · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Sep 7, 2026, 1:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Trial Regarding the Acceptability of Audiotape Intimate Partner Violence (IPV) Screening

NCT00122395
View directory record Official record
Conditions
Domestic Violence
Interventions
Screening via pen and paper, Screening via audiotape
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
18 Years and older · Female only
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 3, 2006 · Synced Sep 7, 2026, 1:29 PM EDT
Enrolling by invitation Phase 4 Interventional

Fracture Recovery for Returning to Duty (Teriparatide STRONG)

NCT04589819
View directory record Official record
Conditions
Stress Fracture of Tibia or Fibula
Interventions
Teriparatide, Placebos
Drug
Lead sponsor
University of South Carolina
Other
Eligibility
Not listed
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 12, 2023 · Synced Sep 7, 2026, 1:29 PM EDT
Completed Not applicable Interventional Results available

Comparative User Experiences With BD Nano™ PRO 32G Extra Thin Wall Pen Needle vs the Terumo Nanopass® 34G Pen Needle

NCT03878745
View directory record Official record
Conditions
Diabetes
Interventions
Terumo Nanopass® 34G pen needle, BD Nano™ PRO 32G pen needle
Device
Lead sponsor
Becton, Dickinson and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
2
States / cities
San Mateo, California • Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated May 18, 2020 · Synced Sep 7, 2026, 1:29 PM EDT
Active, not recruiting Phase 2 Interventional

Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery

NCT03841058
View directory record Official record
Conditions
Spinal Fusion
Interventions
Abaloparatide, Placebo
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
50 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 7, 2026, 1:29 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Baby Steps to Care

NCT07499648
View directory record Official record
Conditions
Prenatal Follow Up Care
Interventions
Care Box
Behavioral
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 7, 2026, 1:29 PM EDT
Withdrawn Early Phase 1 Interventional

Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A Pilot Study

NCT04252612
View directory record Official record
Conditions
Cutaneous Squamous Cell Carcinoma
Interventions
Pramlintide
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Sep 7, 2026, 1:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The OHSU Pregnancy Exercise & Nutrition (PEN) Program

NCT01719406
View directory record Official record
Conditions
Gestational Diabetes
Interventions
Intervention, behavioral lifestyle education
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 14, 2014 · Synced Sep 7, 2026, 1:29 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Exenatide for Treating Cocaine Use Disorder

NCT04941521
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
Exenatide 2 mg [Bydureon], Drug Counseling
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 60 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2022 · Synced Sep 7, 2026, 1:29 PM EDT
Completed Phase 1 Interventional

A Study to Determine the Patient Preference Between Zosano Pharma Parathyroid Hormone (ZP-PTH) Patch and Forteo Pen

NCT02478879
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
ZP-PTH, FORTEO
Drug
Lead sponsor
Zosano Pharma Corporation
Industry
Eligibility
55 Years to 85 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Aug 22, 2016 · Synced Sep 7, 2026, 1:29 PM EDT